Mary Davis
Psychiatric/Mental Health · Marion, OHNPI 1841549391
Payments from drug & device makers
Across 182 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$896
- Neurocrine Biosciences, Inc.$218
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$212
- Otsuka America Pharmaceutical, Inc.$201
- Sunovion Pharmaceuticals Inc.$196
- Vanda Pharmaceuticals Inc.$190
- plus $782 from 9 others
What the payments were for
- Food & beverage$2,64798%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $896 |
| Neurocrine Biosciences, Inc. | 11 | $218 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $212 |
| Otsuka America Pharmaceutical, Inc. | 12 | $201 |
| Sunovion Pharmaceuticals Inc. | 14 | $196 |
| Vanda Pharmaceuticals Inc. | 7 | $190 |
| Alkermes, Inc. | 9 | $155 |
| Johnson & Johnson | 10 | $150 |
| Teva Pharmaceuticals USA, Inc. | 8 | $117 |
| Indivior Inc. | 5 | $102 |
| Lundbeck LLC | 6 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $65 |
| Axsome Therapeutics, Inc. | 3 | $45 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
How this compares
$2,694 in reported general payments places this provider in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 21 | $189,428 |
| Invega SustennaPaliperidone Palmitate | 48 | $156,310 |
| VraylarCariprazine Hcl | 32 | $45,388 |
| AristadaAripiprazole Lauroxil | 11 | $37,406 |
| RexultiBrexpiprazole | 20 | $30,546 |
| TrintellixVortioxetine Hydrobromide | 36 | $17,727 |
| Lurasidone Hcl | 95 | $17,309 |
| Clozapine | 70 | $8,038 |
| Atomoxetine Hcl | 62 | $5,661 |
| Ziprasidone Hcl | 62 | $4,890 |
| Aripiprazole | 96 | $3,856 |
| Hydroxyzine Hcl | 140 | $2,775 |
| Paliperidone ErPaliperidone | 18 | $2,264 |
| Vilazodone Hcl | 11 | $2,088 |
| Buspirone Hcl | 140 | $2,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $150 | $345,73869 claims |
| AbbVieVraylar | $896 | $45,38832 claims |
| Alkermes, Inc.Aristada | $155 | $37,40611 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $201 | $30,54620 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $65 | $17,72736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Marion
- Robin SiefkerMarion$12K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Terri PopovitzCincinnati$161K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.